Pineal-derived tetrapeptide bioregulator (Khavinson school)
Epitalon
Ala-Glu-Asp-Gly (AEDG) — a synthetic tetrapeptide developed as a distilled active fragment of the pineal extract Epithalamin
Overview
Epitalon is not, editorially speaking, one compound. It is the endpoint of a scientific tradition — the Khavinson-school 'peptide bioregulator' program at the St. Petersburg Institute of Bioregulation and Gerontology — that spent five decades characterising short peptides derived from tissue-specific extracts and proposing that they act as endogenous regulators of gene expression. Every methodological choice in the Epitalon literature reflects that origin: the endpoints (pineal function, telomerase, long-term mortality curves), the trial designs (open-label geriatric cohorts, decade-long follow-ups), the journals (Bulletin of Experimental Biology and Medicine, Neuroendocrinology Letters, Advances in Gerontology), and the framing (bioregulation, not receptor pharmacology).
The compound itself is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, often written AEDG. Its historical predecessor is Epithalamin — a bovine pineal-gland extract characterised in the 1970s and registered in Russia for parenteral geriatric use. Epitalon is the isolated peptide proposed to carry that preparation's activity. The two are related but not interchangeable: one is a whole-tissue extract with an old Russian regulatory identity, the other is a four-amino-acid synthetic that came out of the bioregulator program's effort to distill and study individual active sequences. English-language sources sometimes conflate them, and the alternate spelling 'Epithalon' further blurs the picture. A reader who wants to trace the actual evidence base needs to know which molecule is being discussed at every point.
The reported effects, drawn overwhelmingly from Khavinson-school work, cluster around pineal and circadian endpoints: normalisation of melatonin rhythms in aged animals, changes in cognitive and psychomotor endpoints in geriatric cohorts, restoration of aged retinal function, and — most striking and most cited — elevation of telomerase activity in cultured somatic cells. The Anisimov/Khavinson 2003 Neuroendocrinology Letters cohort report described favourable long-term mortality-curve differences in an institutional geriatric population receiving Epitalon or Epithalamin. These are not casual observations, but they were also not conducted under ICH-GCP frameworks and their independent external replication is limited.
The telomerase claim in particular deserves careful reading. The most-cited in-vitro finding — Khavinson 2003 in Bulletin of Experimental Biology and Medicine — described telomere elongation and telomerase activity in cultured human somatic cells after AEDG exposure. That is a real published observation. It is also an in-vitro finding from within the same laboratory program that developed the compound, in a cell system, and its extrapolation to whole-organism lifespan extension in humans is not something the evidence base can currently support. A page that reproduces the telomerase framing as established fact is doing its reader a disservice.
Quick Facts & Evidence
- Category
- Pineal-derived tetrapeptide bioregulator (Khavinson school)
- Research area
- Bioregulator peptide
- Most studied for
- Pineal and circadian function (Khavinson-school preclinical and clinical work)
- Cognitive and psychomotor endpoints in aged cohorts (geriatric observational)
- Telomerase activation in cultured somatic cells (in vitro)
- Melatonin rhythm restoration in aged animal models
- Long-term mortality-curve observations in Russian geriatric cohorts
- Clinical status
- Research use only — no approved clinical indication
- Human evidence
- Preclinical Evidence
- Regulatory status
- Russia — Epitalon is the synthetic tetrapeptide distillation of an older bovine pineal-extract preparation, Epithalamin (Эпиталамин), which has been registered in Russia for parenteral use in geriatric contexts. The two are related but not identical: Epithalamin is a whole-tissue extract characterised in the 1970s; Epitalon (AEDG) is the isolated proposed active tetrapeptide, subsequently synthesised and studied under the peptide-bioregulator framework developed by Khavinson and colleagues.
Preclinical Evidence
Data are from animal models, cell studies, or anecdotal community reports. No controlled human evidence.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format
This page covers the RUO lyophilized synthetic Epitalon (AEDG) vial reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention. The Russian Epithalamin pineal-extract preparation is a separate regulated presentation and is not this profile.
Epitalon research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 10 mg |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 5.0 mL |
| Final concentration | 2 mg/mL |
| How it's given | Subcutaneous injection |
| Research dose | 0.5 mg |
| Frequency | 5×/week, Monday–Friday, during a cycle |
| Duration | 1 month on / 5 months off; twice yearly (Khavinson-school cycling) |
Reported Dosing
The practitioner-reference research protocol for Epitalon is 0.5 mg per subcutaneous injection, 5 times per week (Monday–Friday), during a 4-week cycle repeated twice yearly with 5-month washouts. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 0.5 mg | 5×/week, Mon–Fri, subcutaneous | 1 month on / 5 months off, twice yearly | 0.25 mL at 2 mg/mL; one 10 mg vial = one 4-week cycle |
Why protocols vary
The Khavinson-school framing is that Epitalon acts as a peptide bioregulator triggering telomerase-associated cycles rather than a receptor agonist requiring continuous exposure. Short intensive courses with long washouts are what the source literature evaluated.
Twice-yearly cadence with 5-month washouts matches the Khavinson trial design; extending continuous use is outside the source-literature evidence base.
Preparing the Solution
Turning the freeze-dried powder into a measurable liquid.
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 10 mg vial
Diluent: 5.0 mL bacteriostatic water
Final concentration: 2 mg/mL
Vial and volume from the practitioner reference; concentration calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
5mL
Resulting concentration
2 mg/mL
Equivalent volume
The reported research amount of 0.5 mg is contained within
0.25mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 10 mg ÷ 5 mL = 2 mg/mL
- Bacteriostatic water to match the documented concentration
- 10 mg ÷ 2 mg/mL = 5 mL
- Equivalent volume at this concentration
- 0.5 mg ÷ 2 mg/mL = 0.25 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner referenceResearch-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, 5×/week Mon–Fri during a cycle
Documented in the practitioner reference · Research-practitioner guide
Why this method
Epitalon (AEDG) is a tetrapeptide; the subcutaneous route delivers it into circulation without the gastrointestinal degradation that would break the molecule down.
Systemic subcutaneous dosing is used because the mechanism relies on pineal-signalling and telomerase-associated pathways that require systemic reach, not on a localised depot.
Injection sites reported
- Abdomen (rotate sites)
- Front of the thigh
- Back of the upper arm
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light
- Do not freeze
General RUO practice · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within 7–10 days
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises standard RUO peptide handling for the synthetic AEDG presentation obtained through Western supply channels. The Russian Epithalamin pineal-extract preparation has its own regulatory documentation and does not carry over.
Common Cycle
The practitioner reference frames Epitalon as short intensive courses with long washouts — one of the best-evidenced cycling protocols in the Guide.
- Cycle Length
- 4 weeks on per cycle
- Break Before the Next Cycle
- 5-month washout between cycles; twice yearly
- What the Research Shows
- Khavinson-school long-term mortality follow-ups have run ≥12 years in geriatric cohorts
Documented in the practitioner reference; Khavinson research · Research-practitioner guide
Long-term follow-ups above are for the Russian Epithalamin pineal-extract preparation. Extrapolation to synthetic AEDG is not one-to-one.
Compound Overview
Current areas of research
The following are effects reported in Khavinson-school research and in limited Russian clinical work. Regulatory approval does not exist for any indication in Western jurisdictions.
- Reported normalisation of melatonin rhythm in aged animal models (Khavinson lab)
- Reported cognitive endpoint improvements in Russian geriatric cohort studies (Anisimov, Khavinson 2003)
- Reported telomere elongation and telomerase activity elevation in cultured human somatic cells (Khavinson 2003 in-vitro)
- Reported favourable long-term mortality-curve differences in institutional Russian geriatric cohort observations (Anisimov, Khavinson 2003)
- Reported retinal function endpoint changes in Russian aged-cohort ophthalmology work
Mechanism of action
Epitalon is not, editorially speaking, one compound. It is the endpoint of a scientific tradition — the Khavinson-school 'peptide bioregulator' program at the St. Petersburg Institute of Bioregulation and Gerontology — that spent five decades characterising short peptides derived from tissue-specific extracts and proposing that they act as endogenous regulators of gene expression. Every methodological choice in the Epitalon literature reflects that origin: the endpoints (pineal function, telomerase, long-term mortality curves), the trial designs (open-label geriatric cohorts, decade-long follow-ups), the journals (Bulletin of Experimental Biology and Medicine, Neuroendocrinology Letters, Advances in Gerontology), and the framing (bioregulation, not receptor pharmacology).
The compound itself is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, often written AEDG. Its historical predecessor is Epithalamin — a bovine pineal-gland extract characterised in the 1970s and registered in Russia for parenteral geriatric use. Epitalon is the isolated peptide proposed to carry that preparation's activity. The two are related but not interchangeable: one is a whole-tissue extract with an old Russian regulatory identity, the other is a four-amino-acid synthetic that came out of the bioregulator program's effort to distill and study individual active sequences. English-language sources sometimes conflate them, and the alternate spelling 'Epithalon' further blurs the picture. A reader who wants to trace the actual evidence base needs to know which molecule is being discussed at every point.
The reported effects, drawn overwhelmingly from Khavinson-school work, cluster around pineal and circadian endpoints: normalisation of melatonin rhythms in aged animals, changes in cognitive and psychomotor endpoints in geriatric cohorts, restoration of aged retinal function, and — most striking and most cited — elevation of telomerase activity in cultured somatic cells. The Anisimov/Khavinson 2003 Neuroendocrinology Letters cohort report described favourable long-term mortality-curve differences in an institutional geriatric population receiving Epitalon or Epithalamin. These are not casual observations, but they were also not conducted under ICH-GCP frameworks and their independent external replication is limited.
The telomerase claim in particular deserves careful reading. The most-cited in-vitro finding — Khavinson 2003 in Bulletin of Experimental Biology and Medicine — described telomere elongation and telomerase activity in cultured human somatic cells after AEDG exposure. That is a real published observation. It is also an in-vitro finding from within the same laboratory program that developed the compound, in a cell system, and its extrapolation to whole-organism lifespan extension in humans is not something the evidence base can currently support. A page that reproduces the telomerase framing as established fact is doing its reader a disservice.
- A synthetic tetrapeptide (AEDG, Ala-Glu-Asp-Gly) developed within the Khavinson-school Russian 'bioregulator' tradition, distilled from the older Epithalamin pineal extract
- Evidence base is exceptionally concentrated — geographically, institutionally, and philosophically — in a single scientific tradition, which is a characteristic to name, not a disqualification
- The most-cited claim (telomerase activation) rests on in-vitro work from within the developing laboratory; independent external replication in humans is limited
Human research
The Epitalon research base is defined by two characteristics that are unusual even for a research-only peptide: its geographic concentration and its philosophical framework. Almost all foundational Epitalon and Epithalamin work emerges from the St. Petersburg Institute of Bioregulation and Gerontology (formerly the Leningrad Institute) and its collaborating investigators — primarily Vladimir Khavinson and Vladimir Anisimov. Almost all of it operates within the 'peptide bioregulator' framework: the proposition that short peptides isolated from tissue-specific extracts act as endogenous regulators of gene expression in the tissues from which they were derived. Reading the Epitalon literature without holding that framework in mind produces persistent confusion, because the framework shapes every methodological choice.
The most-cited individual finding is Khavinson et al. 2003 in Bulletin of Experimental Biology and Medicine, which reported elongation of telomeres and elevation of telomerase activity in cultured human somatic cells after AEDG exposure. This is a real published observation, and it has been reproduced within the Khavinson program in follow-up work. It has not been replicated at scale by independent external laboratories, and — critically — it is an in-vitro observation in a cell system, not a demonstration of in-vivo human lifespan extension. The distance between those two things is the distance most Epitalon marketing collapses.
The most consequential clinical observation is the Anisimov/Khavinson 2003 Neuroendocrinology Letters report on institutional Russian geriatric cohorts, describing favourable long-term mortality-curve differences in participants receiving Epithalamin or AEDG. The observation is not casual — the cohorts were followed for years — but the trial designs are not ICH-GCP-standard placebo-controlled RCTs. Whether the mortality-curve differences reflect the compound's activity or the confounders that unblinded institutional-cohort designs are prone to is a question the primary literature does not adjudicate.
Khavinson BEBM 2003 (telomerase)
In-vitro study of AEDG (Epitalon) in cultured human somatic cells. Reported elongation of telomeres and elevation of telomerase activity after peptide exposure. The single most-cited Epitalon finding in Western consumer discourse. Real observation, real journal — but in-vitro from within the developing laboratory, not an in-vivo human lifespan demonstration.
Anisimov/Khavinson NEL 2003 (mortality cohort)
Institutional Russian geriatric cohort study of Epithalamin and AEDG. Long follow-up; reported favourable long-term mortality-curve differences vs comparison. The study design is not an ICH-GCP RCT, and independent external replication of the mortality-curve finding is limited, but the observation is not casual.
Khavinson AEDG mechanism review 2003 NEL
Consolidating review of the AEDG peptide-bioregulator framework: proposed gene-expression modulation, pineal-axis endpoints, and cross-tissue effects. The methodological framework for reading the Khavinson-program literature.
Korkushko BEBM 2006 (cardiovascular geriatric)
Russian geriatric cardiovascular cohort study of Epithalamin. Reported endpoint changes in aged patients across long follow-up. Illustrates the Khavinson program's characteristic geriatric-cohort design applied outside pineal endpoints.
Khavinson 2020 bioregulator framework review
Later consolidating review of the peptide-bioregulator program covering AEDG and related short peptides. Useful as a framework document; not a replication study.
Epitalon has never had an FDA-authorised commercial product, has never completed a phase-2 randomised placebo-controlled trial under an ICH-GCP framework, and does not have an active phase-3 development program under any sponsor known to the Western regulatory registries. That is the essential regulatory position in Europe and North America, and it has been consistent since the compound was first synthesised.
The Russian regulatory picture is different, and it deserves to be described accurately. The pineal-extract preparation Epithalamin — the predecessor to synthetic AEDG — has a registered identity in Russia for parenteral geriatric use, developed within the Soviet-era bioregulator program at what became the St. Petersburg Institute of Bioregulation and Gerontology. The synthetic tetrapeptide Epitalon is not automatically covered by that registration; it is a distinct molecule developed as the proposed active fragment, and its own regulatory identity is narrower.
The WADA prohibited list does not currently include Epitalon by name, but competitive athletes should be aware that peptide bioregulators generally fall under the S0 category (non-approved substances) when they lack an approved therapeutic identity. Verify current WADA status before use in any competitive context.
Safety considerations
Human tolerability data outside the Khavinson-school program are limited. The following draws on the Russian primary literature and research-context observations.
- Injection-site reactions
- Generally reported as well tolerated in Khavinson-school protocols — Adverse-event capture in those studies differs from ICH-GCP conventions; tolerability in ICH-GCP populations is not characterised
- Long-term safety in Western populations is uncharacterised — No FDA or EMA post-marketing dataset exists
- Theoretical telomerase-related considerations — A compound proposed to elevate telomerase activity warrants caution in oncology contexts even where the in-vivo human evidence is limited
There is no approved-label list of contraindications in Western jurisdictions because there is no Western approved indication. The considerations below draw on the compound's proposed mechanisms and on its distinctive regulatory geography.
- Active or recent malignancy — theoretical caution given proposed telomerase-related effects on cellular replicative capacity
- Pregnancy and breastfeeding — no human safety data
- Known hypersensitivity to the compound or excipients
- Concurrent use with exogenous melatonin or other pineal-axis modulating agents warrants clinical caution
- Concurrent use with anti-cancer therapies is mechanistically counter-directional if the telomerase claims translate to humans; oncologist input recommended
Monitoring
- Injection-site reactions across rotation sites
- Response within a defined cycled short course rather than open-ended use, given the absence of long-term Western safety data
- Any new symptoms suggesting hypersensitivity or unexpected endocrine effect
Frequently asked questions
Is Epitalon the same as Epithalon or Epithalamin?
Epitalon and Epithalon are two spellings of the same synthetic tetrapeptide (Ala-Glu-Asp-Gly, AEDG). Both spellings appear in the primary literature and in commercial supplier catalogs. Epithalamin, however, is a different substance: a bovine pineal-gland extract characterised in the 1970s and registered in Russia for parenteral geriatric use. AEDG was distilled as the proposed active fragment of that extract. The two are related in origin but chemically distinct — one is a whole-tissue extract, the other is a defined four-amino-acid peptide. Sources that use the terms interchangeably introduce confusion.
What does the telomerase claim actually rest on?
The most-cited telomerase finding is Khavinson et al. 2003 in Bulletin of Experimental Biology and Medicine, which reported telomere elongation and elevated telomerase activity in cultured human somatic cells after AEDG exposure. That is an in-vitro observation from within the developing laboratory. It is real, it is published, and it has been reproduced in follow-up work by the same program. It has not been shown at the same level of rigour by independent external laboratories, and it is critically NOT a demonstration of in-vivo lifespan extension in humans. The distance between an in-vitro telomerase measurement and a whole-organism longevity claim is the distance most Epitalon marketing collapses.
Why is almost all the research from Russia?
The compound emerged from the Soviet-era peptide-bioregulator program at what became the St. Petersburg Institute of Bioregulation and Gerontology, led over decades by Vladimir Khavinson and colleagues. That program had its own tradition, its own methodological conventions, and its own preferred journals, and it operated at a scale and continuity that Western laboratories did not replicate. This is a characteristic to name, not a disqualification. But it does mean the evidence base has essentially no independent external replication of its key claims, which matters when weighing what the evidence supports.
What is Epitalon's regulatory status?
In the US: not FDA-approved for any indication; no completed phase-2 or phase-3 US trial; access is via research-supply channels. In the EU: not EMA-authorised. In Russia: the whole-tissue predecessor Epithalamin has its own registered identity for parenteral geriatric use, but that registration does not automatically transfer to the synthetic AEDG tetrapeptide sold through Western research-supply channels. The regulatory identity depends on the specific preparation, and consumers should not assume the Russian regulatory framing applies to a research-supply Western vial.
How should I read Epitalon marketing that promises lifespan extension?
Skeptically. The evidence base contains a genuinely intriguing in-vitro telomerase observation and a set of Russian geriatric-cohort mortality-curve reports that are not ICH-GCP RCTs. There is no independently replicated demonstration of lifespan extension in humans. Marketing that translates 'in-vitro telomerase activity' or 'Russian cohort mortality differences' into 'clinically demonstrated life extension' is not tracking the primary literature. A page that reproduces that framing without qualification is doing its reader a disservice.
References
- [1]
Peptides and Ageing: the AEDG peptide bioregulator framework and its application to gerontology — Khavinson VKh, Anisimov VN, Neuroendocrinology Letters (2003)
- [2]
Effect of Epitalon on biomarkers of aging, life span and spontaneous tumour incidence in female Swiss-derived SHR mice — Anisimov VN, Khavinson VKh, Popovich IG, et al., Mechanisms of Ageing and Development (2003)
- [3]
Peptide AEDG (Epitalon) elongates telomeres and increases telomerase activity in human somatic cells — Khavinson VKh, Bondarev IE, Butyugov AA, Bulletin of Experimental Biology and Medicine (2003)
- [4]
Peptide geroprotector Epithalamin: effect on cardiovascular endpoints in aged patients — Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bulletin of Experimental Biology and Medicine (2006)
- [5]
Peptide regulation of ageing: 40 years of the research at the St. Petersburg Institute of Bioregulation and Gerontology — Khavinson VKh, Advances in Gerontology (2020)
- [6]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.
Related on Healthy Mango
Categories